Shin Nippon Biomedical Laboratories, Ltd. (JP:2395) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Shin Nippon Biomedical Laboratories’ subsidiary, Satsuma Pharmaceuticals, has resubmitted its New Drug Application for STS101, a treatment for acute migraine, to the FDA, addressing previous concerns about formulation while receiving no requests for additional clinical trials. This move is seen as pivotal in offering new options for migraine sufferers.
For further insights into JP:2395 stock, check out TipRanks’ Stock Analysis page.